Mumps is a notifiable disease in the entire region. Denmark, Norway and Sweden report both laboratory confirmed cases and cases epidemiologically linked to a laboratory confirmed case. Estonia and Lithuania report both laboratory confirmed cases and typical clinical cases without laboratory confirmation. In addition, Estonia also report cases epidemiologically linked to a laboratory confirmed case. Finland, Iceland and Northwest Russia only report laboratory confirmed cases.
Figure 24. Number of cases of mumps notified in 2003 per 100 000 population (1).
Following the introduction of the measles-mumps-rubella (MMR) vaccine in the national vaccination programmes in the early 1980s, mumps has become a rare disease in all the Nordic countries. This is mainly as a result of high vaccination coverage over several years. In contrast, lower vaccination coverage in the early 1990s in areas of the eastern part of the region resulted in an unstable situation with periodic outbreaks. Changes in vaccination schedule and vaccination campaigns have in the last few years improved the situation.
Vaccination, either as a combined mumps-measles vaccine or as part of the MMR-vaccine, is the best measure to decrease the incidence and subsequent outbreaks of mumps. In all countries in the region mumps vaccine is given as part of the national vaccination programmes. The vaccination coverage in the eastern part of the area has improved in the last few years.
EpiNorth c/o Department of Infectious Disease Epidemiology, Norwegian Institute of Public Health, P.O.Box 4404 Nydalen, N-0403 Oslo, Norway. Tel: + 47 21 07 67 45, Fax: + 47 21 07 65 13, E-mail: